Skip to main content

USPTO Publishes Nine RNAi-Related Patent Applications

Premium
Title: Methods of Producing microRNAs
 
Number: 20070044164
 
Filed: May 31, 2006
 
Lead Inventor: Ross Dickins, Cold Spring Harbor Laboratory
 
“The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene,” the patent application’s abstract states. “In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.”
 

 
Title: RNAi Modulation of Rho-A Gene in Research Models
 
Numbers: 20070044161and20070042984
 
Filed: July 21, 2006
 
Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals
 
“The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides,” the patent applications’ abstracts state.
 

 
Title: Methods of Modulating VEGF-C
 
Numbers: 20070042986
 
Filed: Oct. 24, 2006
 
Lead Inventor: Douglas Trask, University of Iowa
 
According to the patent application’s abstract, the invention “provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C in cells (e.g., cancer cells).”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acid
 
Numbers: 20070042983
 
Filed: Aug. 20, 2004
 
Lead Inventor: Peter Haeberli, Sirna Therapeutics (Merck)
 
This invention “relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid molecules,” the patent application’s abstract states. In particular, the invention “features small nucleic acid molecules … methods used to modulate the expression of genes, such as expressed pseudogenes associated with the maintenance or development of diseases, disorders, traits, and conditions in a subject or organism.”
 

 
Title: Bioinformatically Detectable Group of Novel Regulatory Bacterial and Bacterial-Associated Oligonucleotides and Uses Thereof
 
Numbers: 20070042982
 
Filed: April 2, 2004
 
Lead Inventor: Isaac Bentwich, Rosetta Genomics
 
According to the patent application’s abstract, the invention “relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotides, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotides. GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various bacterial diseases,” the abstract states. “Nucleic acid molecules are provided respectively encoding 6444 GAM precursors oligonucleotides, and 726 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”
 

 
Title: Use of Eukaryotic Genes Affecting Chromatin Separation for Diagnosis and Treatment of Proliferative Diseases
 
Numbers: 20070042981
 
Filed: Sept. 15, 2004 PCT Filed: Sept. 115, 2004
 
Lead Inventor: Christophe Echeverri, Cenix BioScience
 
The invention “relates to the significant functional role of several C. elegans genes and of their corresponding gene products in chromatin separation during cell division that could be identified by means of RNA-mediated interference and to the identification and isolation of functional orthologs of said genes including all biologically functional derivatives thereof,” the patent application’s abstract states. “The invention further relates to the use of said genes and gene products (including said orthologs) in the development or isolation of anti-proliferative agents, particularly their use in appropriate screening assays, and their use for diagnosis and treatment of proliferative and other diseases. In particular, the invention relates to the use of small interfering RNAs derived from said genes for the treatment of proliferative diseases.”
 

 
Title: Bioinformatically Detectable Group of Novel Regulatory Viral and Viral-Associated Oligonucleotides and Uses Thereof
 
Numbers: 20070042381
 
Filed: May 26, 2004
 
Lead Inventor: Isaac Bentwich, Rosetta Genomics
 
The invention “relates to a first group of novel viral and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotides, and a second group of novel operon-like viral and human polynucleotides, here identified as Genomic Record or GR polynucleotides,” the patent application’s abstract states. “GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 1,655 viral and 105,537 human GAM precursor oligonucleotides, and 190 viral and 14,813 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”
 

 
Title: Bioinformatically Detectable Group of Novel Regulatory Oligonucleotides and Uses Thereof
 
Numbers: 20070042380
 
Filed: May 14, 2004
 
Lead Inventor: Isaac Bentwich, Rosetta Genomics
 
The invention “relates to a first group of novel oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotides, and a second group of novel operon-like polynucleotides, here identified as Genomic Record or "GR" polynucleotides,” the patent application’s abstract states. “GAM oligonucleotides selectively inhibit translation of known "target" genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof,” it adds.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.